1. Home
  2. KLTR vs TLSI Comparison

KLTR vs TLSI Comparison

Compare KLTR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaltura Inc.

KLTR

Kaltura Inc.

HOLD

Current Price

$1.38

Market Cap

218.0M

Sector

Technology

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.87

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLTR
TLSI
Founded
2006
2010
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.0M
270.2M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
KLTR
TLSI
Price
$1.38
$4.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$7.00
AVG Volume (30 Days)
210.6K
95.6K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
61.90
N/A
EPS
N/A
N/A
Revenue
$180,854,000.00
$45,151,000.00
Revenue This Year
$2.96
$35.45
Revenue Next Year
$4.96
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
1.20
53.41
52 Week Low
$1.06
$2.20
52 Week High
$2.05
$7.95

Technical Indicators

Market Signals
Indicator
KLTR
TLSI
Relative Strength Index (RSI) 35.77 48.60
Support Level $1.32 $4.70
Resistance Level $1.53 $5.58
Average True Range (ATR) 0.05 0.28
MACD -0.02 -0.02
Stochastic Oscillator 2.27 43.33

Price Performance

Historical Comparison
KLTR
TLSI

About KLTR Kaltura Inc.

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: